Bimekizumab
Product Specifications
UNSPSC Description
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation[1].
Target Antigen
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bimekizumab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Bimekizumab]
References & Citations
[1]Shah M, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6(2):e001306.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99280/Bimekizumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99280/Bimekizumab-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
1418205-77-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6286737-01 0.2 mL
CLEC9A, ID (CLEC9A, C-type lectin domain family 9 member A) (FITC)
Ask
View Details 
MBS6286737-02 5x 0.2 mL
CLEC9A, ID (CLEC9A, C-type lectin domain family 9 member A) (FITC)
Ask
View Details